



## **Cosmo Pharmaceuticals Files Marketing Authorization Application for Methylene Blue MMX 200 mg Tablets with European Medicines Agency**

**Dublin – February 12, 2019** – Cosmo Pharmaceuticals N.V. (SIX: COPN) today announced the filing of a Marketing Authorization Application for Methylene Blue MMX 200 mg tablets with the European Medicines Agency (EMA). Methylene Blue MMX is intended as an aid for the visualization and the detection of lesions in subjects undergoing colonoscopy.

The dossier has been granted the Centralized Authorization Procedure in light of the interests of the patients. This means that, if approval will be granted, such approval will be automatically effective in all EU Member States. The review procedure is expected to be concluded within 12 months.

“While we wait for the outcome of the FDA appeal, we continue to pursue the objective of bringing Methylene Blue MMX to other markets. The EMA filing is another positive step toward bringing this innovative drug to patients and endoscopists,” said Alessandro Della Chà, CEO Cosmo Pharmaceuticals.

### **About Cosmo Pharmaceuticals**

Cosmo is a specialty pharmaceutical company that aims to become a global leader in the field of optimized therapies for selected Gastrointestinal Disorders and Endoscopic Procedures. The Company’s proprietary clinical development pipeline specifically addresses innovative treatments for IBD, such as Ulcerative Colitis and Crohn’s Disease, and Colon Infections. In addition, the Company has developed and launched Eleview, a medical device for polyp and adenoma excision, in the U.S. and it has filed the NDA for Methylene Blue MMX, a diagnostic drug for the detection of lesions during colonoscopy. In addition, new chemical entities are being developed by its associate company Cassiopea S.p.A. for the topical treatment of skin diseases. Cosmo’s MMX drugs already on the market are Lialda/ Mezavant/Mesavancol, a treatment for IBD that is licensed globally to Giuliani and Shire Limited and Uceris, the first glucocorticosteroid indicated for the induction of remission in active, mild to moderate Ulcerative Colitis, licensed in US to Santarus/Salix/Valeant and in the Rest of the World to Ferring as Cortiment. The FDA has also recently approved Aemcolo, Cosmo’s first antibiotic for the treatment of Travelers’ Diarrhea. Cosmo’s proprietary MMX technology is at the core of the Company’s product pipeline and was developed from its expertise in formulating and manufacturing gastrointestinal drugs for international clients at its GMP (Good Manufacturing Practice) facilities in Lainate, Italy. The technology is designed to deliver active ingredients in a targeted manner in the colon. For further information on Cosmo, please visit the Company’s website: [www.cosmopharma.com](http://www.cosmopharma.com)

**Next events**

Full-year results 2018 reporting  
Annual General Meeting

March 29, 2019  
May 2019

**Contact:**

John Manieri, Head of Investor Relations  
Cosmo Pharmaceuticals N.V.  
Tel: +353 1 817 03 70  
jmanieri@cosmopharma.com

**Disclaimer**

Some of the information contained in this press release contains forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. Cosmo undertakes no obligation to publicly update or revise any forward-looking statements.

This communication is not an offer of securities of any issuer. Securities may not be offered or sold in the United States absent registration or an exemption from the registration requirement of the US Securities Act of 1933.

This press release constitutes neither an offer to sell nor a solicitation to buy securities and it does not constitute a prospectus within the meaning of article 652a and/or 1156 of the Swiss Code of Obligations or a listing prospectus within the meaning of the listing rules of the SIX Swiss Exchange or any similar document. The offer will be made solely by means of, and on the basis of, a securities prospectus to be published. An investment decision regarding the securities to be publicly offered should only be made on the basis of the securities prospectus.

This press release is made to and directed only at (i) persons outside the United Kingdom, (ii) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order"), and (iii) high net worth individuals, and other persons to whom it may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order. Any person who is not a relevant person should not act or rely on this press release or any of its contents.

This press release does not constitute an "offer of securities to the public" within the meaning of Directive 2003/71/EC of the European Union (the "Prospectus Directive") of the securities referred to in it (the "Securities") in any member state of the European Economic Area (the "EEA"). Any offers of the Securities to persons in the EEA will be made pursuant to an exemption under the Prospectus Directive, as implemented in member states of the EEA, from the requirement to produce a prospectus for offers of the Securities.